JPT Launches Broad Spectrum of COVID-19 Peptide Tools for Immune Monitoring, Vaccine & Diagnostics Development
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: GlobeNewswire
BERLIN, April 22, 2020 (GLOBE NEWSWIRE) -- JPT Peptide Technologies (JPT) announces the launch of ready-to-use peptide tools to study and profile the immune response towards SARS-CoV-2 infection. The products include high content Peptide Microarrays covering all proteins of SARS-CoV-2 and structural antigens of SARS-CoV, MERS-CoV, and common cold coronaviruses, PepMixTM Peptide Pools of many SARS-CoV-2 antigens, Epitope Mapping Sets and individual Epitope Peptides. The recent COVID-19 pandemic has led to a rapidly increased need for high quality peptide tools and services covering the SARS-CoV-2 proteome to gain a deeper understanding of humoral and cellular immunity for vaccine, immunotherapy, and diagnostics developments. In response to the evolving outbreak, JPT has developed a variety of novel, ready-to-use products for detailed and epitope-resolved detection and monitoring of antigen-specific immune responses. These products include a high content SARS-CoV-2 Peptide Mi
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR Newswire
- BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026GlobeNewswire
- BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.MarketBeat
- Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]Yahoo! Finance
- BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People OfficerGlobeNewswire
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 2/12/26 - Form 144
- 1/28/26 - Form 6-K
- 1/14/26 - Form 6-K
- BNTX's page on the SEC website